



Fax completed form to: (855) 840-1678
 If this is an URGENT request, please call (800) 882-4462
 (800.88.CIGNA)

Fasenra (benralizumab)

PHYSICIAN INFORMATION			PATIENT INFORMATION		
* Physician Name:			*Due to privacy regulations we will not be able to respond via fax with the outcome of our review unless all asterisked (*) items on this form are completed.*		
Specialty:	* DEA, NPI or TIN:				
Office Contact Person:			* Patient Name:		
Office Phone:			* Cigna ID:	* Date of Birth:	
Office Fax:			* Patient Street Address:		
Office Street Address:			City:	State:	Zip:
City:	State:	Zip:	Patient Phone:		
Urgency: <input type="checkbox"/> Standard <input type="checkbox"/> Urgent (In checking this box, I attest to the fact that applying the standard review time frame may seriously jeopardize the customer's life, health, or ability to regain maximum function)					
Medication Requested: <input type="checkbox"/> Fasenra 30mg/ml syringe <input type="checkbox"/> Other (please specify): <input type="checkbox"/> Fasenra 30mg/ml Pen					
Directions for use:		Dose:		Quantity:	
Duration of therapy:			ICD10:		
Where will this medication be obtained? <input type="checkbox"/> Accredo Specialty Pharmacy** <input type="checkbox"/> Retail pharmacy <input type="checkbox"/> Prescriber's office stock (billing on a medical claim form) <input type="checkbox"/> Home Health / Home Infusion vendor <input type="checkbox"/> Other (please specify): <small>**Cigna's nationally preferred specialty pharmacy</small>					
<small>**Medication orders can be placed with Accredo via E-prescribe - Accredo (1640 Century Center Pkwy, Memphis, TN 38134-8822 NCPDP 4436920), Fax 888.302.1028, or Verbal 866.759.1557</small>					
Facility and/or doctor dispensing and administering medication: Facility Name: _____ State: _____ Tax ID#: _____ Address (City, State, Zip Code): _____					
Is the requested medication for a chronic or long-term condition for which the prescription medication may be necessary for the life of the patient? <input type="checkbox"/> Yes <input type="checkbox"/> No					
What is your patient's diagnosis? <input type="checkbox"/> asthma			<input type="checkbox"/> other (please specify): _____		
Clinical Information Is your patient currently being treated with another monoclonal antibody (such as Cinqair, Nucala, Xolair)? <input type="checkbox"/> No, not currently - OR - Yes, but this drug will be stopped when the requested drug is started <input type="checkbox"/> Yes, and the patient will continue to use this drug with the requested drug <input type="checkbox"/> unknown (if continuing use) Please provide name of drug and clinical rationale for the combined use of Fasenra and another monoclonal antibody to treat your patient's diagnosis.					
Prior to starting Fasenra, did/does your patient have a dependence on (for at least 50% of the 12 months before the drug requested) or inadequate control with daily oral corticosteroids for maintenance? Yes <input type="checkbox"/> No <input type="checkbox"/>					
(if no) Prior to Fasenra, was your patient maintained on high doses of inhaled corticosteroids (ICS) with an additional controller (long-acting beta-agonist [LABA] or leukotriene receptor antagonist/theophylline)? Yes <input type="checkbox"/> No <input type="checkbox"/>					
(if yes) Which of the following apply to your patient? <input type="checkbox"/> patient had poor symptom control as shown by an Asthma Control Questionnaire (ACT) consistently greater than 1.5 or Asthma Control Test less than 20 <input type="checkbox"/> patient had 2 or more exacerbations requiring at least 3 days of systemic corticosteroids in the 12 months prior to the					

- requested drug
- patient had 1 or more severe exacerbations (hospitalization, ICU stay or mechanical ventilation) in the 12 months prior to the requested drug
 - patient had demonstrated airflow limitation by an FEV1 less than 80% predicted (in the face of reduced FEV1/FVC defined as less than the lower limit of normal) after appropriate bronchodilator withhold
 - none of the above

Does your patient have either of the following?

- blood eosinophil count of 150 cells/mcl or greater within the previous 6 weeks
- history of blood eosinophil count of 300 cells/mcl or greater
- none of the above

Will your patient continue to use an inhaled corticosteroid (ICS) AND another controller therapy (for example, long-acting beta-agonist [LABA], leukotriene receptor) while on Fasentra? Yes No

Additional pertinent information (examples could include past medications tried, labs, pertinent patient history, and names of any agents to be used concurrently):

Attestation: I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan or insurer its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.

Prescriber Signature: _____ **Date:** _____

Save Time! Submit Online at: www.covermy meds.com/main/prior-authorization-forms/cigna/ or via SureScripts in your EHR.

Our standard response time for prescription drug coverage requests is 5 business days. If your request is urgent, it is important that you call us to expedite the request. View our Prescription Drug List and Coverage Policies online at cigna.com.

v101619

"Cigna" is a registered service mark, and the "Tree of Life" logo is a service mark, of Cigna Intellectual Property, Inc., licensed for use by Cigna Corporation and its operating subsidiaries. All products and services are provided by or through such operating subsidiaries and not by Cigna Corporation. Such operating subsidiaries include, for example, Cigna Health and Life Insurance Company and Cigna Health Management, Inc. Address: Cigna Pharmacy Services, PO Box 42005, Phoenix AZ 85080-2005